Synthesis and biological evaluation of novel N1-phenylsulphonyl indole derivatives as potent and selective 5-HT6R ligands for the treatment of cognitive disorders

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 31, Issue , 2016, Pages 1-15

  Nirogi, Ramakrishna V S ^a   Bandyala, Thrinath Reddy ^a,b   Gangadasari, Pamuletinarasimha Reddy ^a   Khagga, Mukkanti ^b  

^a SUVEN LIFE SCIENCES LTD   (India)

^b JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY   (India)

Author keywords

5 Hydroxytryptamine 6 receptor; animal models; central nervous system; cognition; novel object recognition test; structure activity relationship

Indexed keywords

1 [4 METHYL 3 (4 METHYL PIPERAZIN 1 YL METHYL)PHENYLSULFONYL] 1H INDOLE; BENZENE DERIVATIVE; INDOLE DERIVATIVE; SEROTONIN 6 ANTAGONIST; SEROTONIN 6 RECEPTOR; SULFONE DERIVATIVE; UNCLASSIFIED DRUG; 1-(4-METHYL-3-(4-METHYL PIPERAZIN-1-YL METHYL)PHENYLSULFONYL)-1H-INDOLE DIHYDROCHLORIDE; LIGAND; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; SEROTONIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BIOLOGICAL ACTIVITY; COGNITION; COGNITIVE DEFECT; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG HALF LIFE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; PHARMACOKINETIC PARAMETERS; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUME OF DISTRIBUTION; CHEMICAL STRUCTURE; CHEMISTRY; COGNITION DISORDERS; DOSE RESPONSE; METABOLISM; SYNTHESIS;

ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INDOLES; LIGANDS; MOLECULAR STRUCTURE; PIPERAZINES; RECEPTORS, SEROTONIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84994173166     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2015.1103233     Document Type: Article

References (46)

1. Cummings JL, Back C. The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. Am J Geriatr Psychiatry 1998;6:S64–78
2. Garcia-Alloza M, Gil-Bea FJ, Diez-Ariza M, et al. Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease. Neuropsychologia 2005;43:442–9
3. Doody RS, Ferris SH, Salloway S, et al. Donepezil treatment of patients with MCI:a 48-week randomized, placebo-controlled trial. Neurol 2009;72:1555–61
4. Farlow MR, Cummings JL. Effective pharmacologic management of Alzheimer's disease. Am J Med 2007;120:388–97
5. Van Marum RJ. Update on the use of memantine in Alzheimer's disease. Neuropsychiatr Dis Treat 2009;5:237–47
6. 6 receptor-like material in the rat central nervous system. Brain Res 1997;746:207–19
7. 6 receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. Neuropsychopharmacol 2001;25:662–8
8. 6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. Eur J Pharmacol 2006;553:109–19
9. Ramirez MJ, Lai MKP, Tordera RM, Francis PT. Serotonergic therapies for cognitive symptoms in Alzheimer's disease:rationale and current status. Drugs 2014;74:729–36
10. Nirogi R, Kambhampati R, Shinde A, et al. Alzheimer’s and dementia. International conference on Alzheimer’s Disease, Vienna. 2009;5:250
11. Biotie therapies. Available from:http://www.biotie.com/en/product_and_development/development_pipeline/syn120 [last accessed 1 May 2015]
12. Pfizer. Available from:http://www.pfizer.com/sites/default/files/productpipeline/pipeline_2013_0509.pdf/Neuroscience & pain [last accessed 1 May 2015]
13. Avineuro Pharmaceuticals. Available from:http://www.biocentury.com/products/avn-211 [last accessed 1 May 2015]
14. 6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol 2010;13:1021–33
15. GlaxoSmithKline. Available from:http://www.gsk.com/research/our-product-pipeline.html [last accessed 1 May 2015]
16. Ivachtchenko AV, Golovina ES, Kadieva MG, et al. Synthesis and structure−activity relationship (SAR) of (5,7-disubstituted 3-phenylsulfonyl-pyrazolo[1,5-a]pyrimidin-2-yl)-methylamines as potent serotonin 5-HT6 receptor (5-HT6R) antagonists. J Med Chem 2011;54:8161–73
17. Ivachtchenko AV, Dmitriev DE, Golovina ES, et al. (3-Phenylsulfonylcycloalkano[e and d]pyrazolo[1,5-a]pyrimidin-2-yl)amines:potent and selective antagonists of the serotonin 5-HT6 receptor. J Med Chem 2010;53:5186–96
18. Ivachtchenko AV, Golovina ES, Kadieva MG, et al. Antagonists of 5-HT6 receptors. Substituted 3-(phenylsulfonyl) pyrazolo[1,5-a]pyrido[3,4-e]pyrimidines and 3-(phenylsulfonyl) pyrazolo[1,5-a]pyrido[4,3-d]pyrimidines—Synthesis and ‘structure–activity’ relationship. Bioorg Med Chem Lett 2012;22:4273–80
19. Ivachtchenko AV, Golovina ES, Kadieva MG, et al. Synthesis and SAR of 3-arylsulfonyl-pyrazolo[1,5-a]pyrimidines as potent serotonin 5-HT6 receptor antagonists. Bioorg Med Chem 2011;19:1482–91
20. Ivachtchenko AV, Golovina ES, Kadieva MG, et al. 2-Substituted 5,6-dimethyl-3-phenylsulfonyl-pyrazolo[1,5-a]pyrimidines:new series of highly potent and specific serotonin 5-HT6 receptor antagonists. Eur J Med Chem 2011;46:1189–97
21. (a) Glennon RA. Higher-end serotonin receptors:5-HT(5), 5-HT(6), and 5-HT(7). J Med Chem 2003;4:2795–812. (b) Glennon RA, Lee M, Rangisetty JB, et al. 2-Substituted tryptamines:agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem 2000;43:1011–18
22. Liu KG, Robichaud AJ, Bernotas RC, et al. 5Piperazinyl-3-sulfonylindazoles as potent and selective 5-hydroxytryptamine-6 antagonists. J Med Chem 2010;53:7639–46
23. Routledge C, Bromidge SM, Moss SF, et al. Characterization of SB-271046:a potent, selective and orally active 5-HT(6) receptor antagonist. Br J Pharmacol 2000;130:1606–12
24. 6 receptor antagonist. J Med Chem 1999;42:202–5
25. 6 receptor antagonists:prospects for the treatment of cognitive disorders including dementia. Curr Opin Drug Discov Devel 2008;11:642–54
26. 6 receptor antagonists. Bioorg Med Chem Lett 2005;15:4780–5
27. 6 receptor antagonists. Bioorg Med Chem Lett 2005;15:379–83
28. 6 antagonists as potential treatment for cognitive dysfunction. J Drug Dev Res 2009;70:145–68. (c) Beard CC, Clark RD, Fisher LM, et al. US Patent 0073700 A1; 2003
29. 6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer’s disease. J Med Chem 2014;57:7160–81
30. Nirogi R, Daulatabad A, Parandhama G, et al. Synthesis and pharmacological evaluation of aryl aminosulfonamide derivatives as potent 5-HT(6) receptor antagonists. Bioorg Med Chem Lett 2010;20:4440–3
31. Nirogi R, Dwarampudi A, Kambhampati R, et al. Rigidized 1-aryl sulfonyl tryptamines:synthesis and pharmacological evaluation as 5-HT6 receptor ligands. Bioorg Med Chem Lett 2011;21:4577–80
32. 6 receptor antagonists. Bioorg Med Chem Lett 2011;21:346–9
33. 6 receptor ligands. Bioorg Med Chem Lett 2012;22:7431–5. (C) Ramakrishna VSN, Shirsath VS, Kambhampati RS, et al. Narylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them. WO 2004/048330 A1; 2004
34. Ivachtchenko A, Golovina E, Kadieva M, et al. Synthesis of substituted diphenyl sulfones and their structure-activity relationship with the antagonism of 5-НТ6 receptors. Bioorg Med Chem 2013;21:4614–27
35. 6) receptor antagonists. J Med Chem 2005;48:4216–19
36. 6 receptor antagonists. Spec Publ–R Soc Chem 2001;264:101–19
37. Hirst WD, Minton JA, Bromidge SM, et al. Characterization of [(125)I]-SB-258585 binding to human recombinant and native 5-HT(6) receptors in rat, pig and human brain tissue. Br J Pharmacol 2000;130:1597–605
38. 6 receptors. Bioorg Med Chem Lett 2004;14:4569–73
39. 6 serotonin eceptors:receptor modeling studies. J Med Chem 2008;51:603–11
40. 6 serotonin receptors. J Med Chem 2006;49:5217–25
41. 6 receptor ligands:progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacol Ther 2008;17:207–31
42. 6 receptor antagonists. Bioorg Med Chem Lett 2010;20:2133–6
43. 6 serotonin receptor and mutagenesis studies of the third cytoplasmic loop. Brain Res Mol Brain Res 2001;90:110–17
44. 6 receptor-mediated cAMP signaling pathways. Br J Pharmacol 2006;148:1133–43
45. Lewis DFV, Cytochromes P. Structure, function and mechanism. London:Taylor and Francis Publishing; 1996
46. Ennaceur A, Neave N, Aggleton JP. The effects of neurotoxic lesions of the perirhinal cortex combined to fornix transection on object recognition memory in the rat. Behav Brain Res 1997;88:181–93